Mycophenolate mofetil treatment in children and adolescents with lupus

Kazyra, Ina; Pilkington, Clarissa; Marks, Stephen D.; Tullus, Kjell
December 2010
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Dec2010, Vol. 95 Issue 12, p1059
Academic Journal
Safety and efficacy data are presented on the use of mycophenolate mofetil (MMF) in 26 children and adolescents with lupus. Data include therapy before and 12 months after starting MMF. 18 of 26 patients had biopsy-proved lupus nephritis. Group 1 were commenced on MMF induction and/or maintenance therapy (n=14), group 2 converted from azathioprine because of inadequate disease control (n=12). 73% of all (10 (71%) group 1 and 10 (83%) group 2) patients experienced a significant improvement in British Isles Lupus Assessment Group score (from median 9.0 to 3.0). Children with hypocomplementaemia increased their C3 significantly in both groups (0.53-1.15 for group 1 and 0.63-1.2 g/l for group 2, p=0.001), and C4 level only in group 1 (0.08-0.17, p=0.01). Renal function and albuminuria improved in those with active nephritis (p=0.01). Significant improvements were seen in both groups in haemoglobin, erythrocyte sedimentation rate and lymphocyte counts. Prednisolone dose was weaned in both groups, p<0.05. Side-effects were seen in four patients, but none was judged to be severe enough to discontinue treatment. MMF treatment in this cohort of children with lupus seemed to be safe, well tolerated and effective.


Related Articles

  • Mycophenolate mofetil.  // Reactions Weekly;9/21/2013, Issue 1470, p31 

    An abstract of the article "A single-centre retrospective study of the safety and efficacy of mycophenolate mofetil in children and adolescents with nephrotic syndrome," by A. V. Hassan and colleagues is presented.

  • Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Fujinaga, Shuichiro; Someya, Tomonosuke; Watanabe, Tsuneki; Ito, Akira; Ohtomo, Yoshiyuki; Shimizu, Toshiaki; Kaneko, Kazunari // European Journal of Pediatrics;Apr2013, Vol. 172 Issue 4, p513 

    The efficacy of rituximab (RTX) as the sole therapy for preventing relapses of nephrotic syndrome (NS) is transient in most patients; therefore, the optimal therapy required for maintaining a successful response to a biological agent remains a challenge. We conducted a prospective study to...

  • Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. Paller, Amy S.; Siegfried, Elaine C.; Langley, Richard G.; Gottlieb, Alice B.; Pariser, David; Landells, Ian; Hebert, Adelaide A.; Eichenfield, Lawrence F.; Patel, Vaishali; Creamer, Kara; Jahreis, Angelika // New England Journal of Medicine;1/17/2008, Vol. 358 Issue 3, p241 

    Background: Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis. Methods: In this 48-week study,...

  • Lupus, fibrosis, renal failure.  // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_6, pvi14 

    The article presents abstracts on medical topics which include the efficacy of mycophenolate mofetil (MMF) in the treatment of proliferative lupus nephritis, effectiveness and toxicity of tamoxifen (TXF) and prednisone (PDN) in idiopathic retroperitoneal fibrosis (IRF) patients, and the...

  • Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Doycheva, Deshka; Zierhut, Manfred; Blumenstock, Gunnar; Stuebiger, Nicole; Deuter, Christoph // Graefe's Archive of Clinical & Experimental Ophthalmology;Aug2011, Vol. 249 Issue 8, p1235 

    Background: Short-term studies have shown mycophenolate mofetil (MMF) to be a useful immunosuppressive agent for the treatment of intraocular inflammation. The aim of our study was to assess the long-term efficacy and tolerability of MMF in patients with chronic non-infectious uveitis, as well...

  • Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Li, Xiao; Ren, Hong; Zhang, Qianying; Zhang, Wen; Wu, Xiaojing; Xu, Yaowen; Shen, Pingyan; Chen, Nan // Nephrology Dialysis Transplantation;Apr2012, Vol. 27 Issue 4, p1467 

    Background. Although the use of aggressive immunosuppression has improved both patient and renal survival of patients with lupus nephritis (LN), the optimal treatment of LN remains challenging. The objective of this study is to assess the efficacy and safety of mycophenolate mofetil (MMF) and...

  • Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis. Medrano, A. Segarra; Presas, J. Vila; Clavé, L. Pou; Masferrer, J. Majó; Domenech, J. Camps // Nefrologia;2011, Vol. 31 Issue 3, p286 

    Introduction: The combination of cyclosporin A (CsA) and mycophenolate mofetil (MMF) has a synergistic immunosuppressive effect and, as a result, it may induce remission of nephrotic syndrome in patients with steroid- and CsAresistant focal segmental glomerulosclerosis (FSGS). Objective: To...

  • Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. Onishi, Akira; Sugiyama, Daisuke; Tsuji, Go; Nakazawa, Takashi; Kogata, Yoshinori; Tsuda, Kosaku; Naka, Ikuko; Nishimura, Keisuke; Misaki, Kenta; Kurimoto, Chiyo; Hayashi, Hiroki; Kageyama, Goichi; Saegusa, Jun; Sugimoto, Takeshi; Kawano, Seiji; Kumagai, Shunichi; Morinobu, Akio // Modern Rheumatology (Springer Science & Business Media B.V.);Jan2013, Vol. 23 Issue 1, p89 

    Objectives: Recent studies have shown that mycophenolate mofetil (MMF) is similar to intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis (LN), but that treatment response may vary according to location and race/ethnicity. Moreover, no studies have been conducted to compare...

  • Mycophenolate Mofetil Monitoring: Is There Evidence That It Can Improve Outcomes? Byrne, R.; Yost, S. E.; Kaplan, B // Clinical Pharmacology & Therapeutics;Aug2011, Vol. 90 Issue 2, p204 

    In this article the author discusses aspects of using Mycophenolate Mofetil (MMF) Monitoring as the standard drug monitoring for immunosuppressant drug MMF in organ transplantation. Particular focus is given to the therapeutic drug monitoring (TDM) which promotes the effective drug use with...


Read the Article


Sign out of this library

Other Topics